Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

144.47 +0.89 (+0.62%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,702,793
Open 143.05
Bid (Size) 144.20 (5)
Ask (Size) 145.98 (1)
Prev. Close 143.58
Today's Range 142.75 - 145.47
52wk Range 142.75 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Lowest Volatility Dividend Stocks
Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga

Performance

YTD
-9.69%
-9.69%
1 Month
-5.64%
-5.64%
3 Month
-11.99%
-11.99%
6 Month
-2.88%
-2.88%
1 Year
-6.70%
-6.70%

More News

Read More
The Smartest Dividend Stocks to Buy With $500 Right Now
Via The Motley Fool
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Via Benzinga
Exposures Product Safety
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
The Analyst Landscape: 15 Takes On Johnson & Johnson
Via Benzinga
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Via Chartmill
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
Via Benzinga
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
Via Benzinga
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap
Via Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Analyst Reports For Home Depot, Johnson & Johnson & Salesforce
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Celebrating innovation happens from the inside out
Via Brandpoint
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Very Healthy Dividend Stocks to Hold for Decades of Income
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.